Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia

Danielle M. Townsley; Phillip Scheinberg; Thomas Winkler; Ronan Desmond; Bogdan Dumitriu; Olga Rios; Barbara Weinstein; Janet Valdez; Jennifer Lotter; Xingmin Feng; Marie J. Desierto; Harshraj Leuva; Margaret Bevans; Colin O. Wu; André Larochelle; Katherine R. Calvo; Cynthia E. Dunbar; Neal S. Young

doi:10.1056/nejmoa1613878

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The addition of eltrombopag to immunosuppressive therapy was associated with markedly higher rates of hematologic response among patients with severe aplastic anemia than in a historical cohort. (Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov number, NCT01623167 .).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Townsley et al. (2017) studied this question.

synapsesocial.com/papers/69de7c0f7ed287395e559191 https://doi.org/10.1056/nejmoa1613878

View Full Paper

Ask AI

Bookmark

Share

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia

Ask about this paper

Abstract

Discussion

Cite This Study

Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading